159 related articles for article (PubMed ID: 34118892)
41. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan.
Hsu CS; Lang HC; Huang KY; Chao YC; Chen CL
Hepatol Int; 2018 Nov; 12(6):531-543. PubMed ID: 30426396
[TBL] [Abstract][Full Text] [Related]
42. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
43. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
[TBL] [Abstract][Full Text] [Related]
44. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Huang HK; Yeh JI
Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
[TBL] [Abstract][Full Text] [Related]
45. Severe hypoglycemia and hip fracture in patients with type 2 diabetes: a nationwide population-based cohort study.
Hung YC; Lin CC; Chen HJ; Chang MP; Huang KC; Chen YH; Chen CC
Osteoporos Int; 2017 Jul; 28(7):2053-2060. PubMed ID: 28374044
[TBL] [Abstract][Full Text] [Related]
46. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study.
Yang J; Vallarino C; Bron M; Perez A; Liang H; Joseph G; Yu S
Curr Med Res Opin; 2014 Nov; 30(11):2223-31. PubMed ID: 24983744
[TBL] [Abstract][Full Text] [Related]
47. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
Hippisley-Cox J; Coupland C
BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
[TBL] [Abstract][Full Text] [Related]
48. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
49. Diabetes mellitus in patients with cirrhosis: clinical implications and management.
Elkrief L; Rautou PE; Sarin S; Valla D; Paradis V; Moreau R
Liver Int; 2016 Jul; 36(7):936-48. PubMed ID: 26972930
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
51. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
52. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Chan SY; Ou SM; Chen YT; Shih CJ
Int J Cardiol; 2016 Sep; 218():170-175. PubMed ID: 27236110
[TBL] [Abstract][Full Text] [Related]
53. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.
Hung SC; Chang YK; Liu JS; Kuo KL; Chen YH; Hsu CC; Tarng DC
Lancet Diabetes Endocrinol; 2015 Aug; 3(8):605-14. PubMed ID: 26094107
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus.
Cheng CN; Wang CY; Lin HW; Chang TY; Lin HJ; Chou C; Lin FJ
Sci Rep; 2020 Apr; 10(1):5746. PubMed ID: 32238842
[TBL] [Abstract][Full Text] [Related]
55. Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks.
Chen TH; Wang CC; Liu CH; Hsiao CC; Chen ST; Liu FH; Ho MY; Li YR
Endocr Pract; 2020 Aug; 26(8):818-829. PubMed ID: 33471673
[TBL] [Abstract][Full Text] [Related]
56. Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus.
Tseng CH
Eur J Endocrinol; 2019 Jun; 180(6):365-372. PubMed ID: 30986765
[TBL] [Abstract][Full Text] [Related]
57. Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis.
Benmassaoud A; Nitulescu R; Pembroke T; Halme AS; Ghali P; Deschenes M; Wong P; Klein MB; Sebastiani G
Clin Infect Dis; 2019 Sep; 69(8):1422-1430. PubMed ID: 30561558
[TBL] [Abstract][Full Text] [Related]
58. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
59. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
[TBL] [Abstract][Full Text] [Related]
60. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
